The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif, Sheryl L. Windsor, Barry A. Borlaug, Dalane W. Kitzman, Sanjiv J. Shah, Fengming Tang, Yevgeniy Khariton, Ali O. Malik, Taiyeb Khumri, Guillermo Umpierrez, Sumant Lamba, Kavita Sharma, Sadiya S. Khan, Lokesh Chandra, Robert A. Gordon, John J. Ryan, Sunit Preet Chaudhry, Susan M. Joseph, Chen H. Chow, Manreet K. KanwarMichael Pursley, Elias S. Siraj, Gregory D. Lewis, Barry S. Clemson, Michael Fong, Mikhail N. Kosiborod

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds